Cargando…
Canadian Pediatric Neuro-Oncology Standards of Practice
Primary CNS tumors are the leading cause of cancer-related death in pediatrics. It is essential to understand treatment trends to interpret national survival data. In Canada, children with CNS tumors are treated at one of 16 tertiary care centers. We surveyed pediatric neuro-oncologists to create a...
Autores principales: | Bennett, Julie, Erker, Craig, Lafay-Cousin, Lucie, Ramaswamy, Vijay, Hukin, Juliette, Vanan, Magimairajan I., Cheng, Sylvia, Coltin, Hallie, Fonseca, Adriana, Johnston, Donna, Lo, Andrea, Zelcer, Shayna, Alvi, Saima, Bowes, Lynette, Brossard, Josée, Charlebois, Janie, Eisenstat, David, Felton, Kathleen, Fleming, Adam, Jabado, Nada, Larouche, Valérie, Legault, Geneviève, Mpofu, Chris, Perreault, Sébastien, Silva, Mariana, Sinha, Roona, Strother, Doug, Tsang, Derek S., Wilson, Beverly, Crooks, Bruce, Bartels, Ute |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783450/ https://www.ncbi.nlm.nih.gov/pubmed/33415075 http://dx.doi.org/10.3389/fonc.2020.593192 |
Ejemplares similares
-
Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature
por: Arbour, Gabrielle, et al.
Publicado: (2022) -
DIPG in Children – What Can We Learn from the Past?
por: Vanan, Magimairajan Issai, et al.
Publicado: (2015) -
NFB-08. TRAM-01: A Phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas
por: Kiaei, Dorsa Sadat, et al.
Publicado: (2022) -
A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01
por: Perreault, Sébastien, et al.
Publicado: (2019) -
LGG-25. A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. TRAM-01
por: Perreault, Sébastien, et al.
Publicado: (2020)